Literature DB >> 12804849

Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults.

James L Williams1, Dana A Bruden, Henry H Cagle, Brian J McMahon, Susan E Negus, Carol J Christensen, Mary M Snowball, Lisa R Bulkow, Leslie K Fox-Leyva.   

Abstract

Current immunization schedules for hepatitis A vaccine specify administration of a booster within 6-12 or 6-18 months of the primary dose. However, there may be circumstances that disrupt this schedule and the efficacy of administering a booster beyond the recommended time is a practical concern for healthcare providers. In this study, a booster was administered to 268 participants (137: <18 years old), an average of 27 months (range 20-31) after the primary dose. In those tested after the booster, the median anti-HAV GMT was 1544 milli-international units per milliliter (mIU/ml). Response to a delayed booster was strong in children over 2 years old (GMT 1500-1960 mIU/ml) and adults (GMT 1622 mIU/ml), but was significantly lower in children under 2 years old (GMT 1109 mIU/ml). Findings suggest a booster administered 20-31 months after the primary dose is immunogenic and GMT in persons >2 years of age were comparable to those seen in adults and children who receive hepatitis A vaccine per schedule.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804849     DOI: 10.1016/s0264-410x(03)00250-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  A novel process for production of hepatitis A virus in Vero cells grown on microcarriers in bioreactor.

Authors:  Ming-Bo Sun; Yan-Jun Jiang; Wei-Dong Li; Ping-Zhong Li; Guo-Liang Li; Shu-De Jiang; Guo-Yang Liao
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

2.  [Prevention of virus hepatitis A to E].

Authors:  M Cornberg; M P Manns
Journal:  Internist (Berl)       Date:  2011-03       Impact factor: 0.743

3.  Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children.

Authors:  Gregory A Raczniak; Timothy K Thomas; Lisa R Bulkow; Susan E Negus; Carolyn L Zanis; Michael G Bruce; Philip R Spradling; Eyasu H Teshale; Brian J McMahon
Journal:  Vaccine       Date:  2013-03-05       Impact factor: 3.641

Review 4.  Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data.

Authors:  E Vidor; R Dumas; V Porteret; F Bailleux; K Veitch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-06       Impact factor: 3.267

5.  Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.

Authors:  Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris
Journal:  MMWR Recomm Rep       Date:  2020-07-03

6.  Hepatitis A vaccination.

Authors:  Li Zhang
Journal:  Hum Vaccin Immunother       Date:  2020-07-10       Impact factor: 3.452

7.  Persistence of immunity from 1 year of age after one or two doses of hepatitis A vaccine given to children in Argentina.

Authors:  Carlos Espul; Laura Benedetti; Héctor Cuello; Guy Houillon; Anvar Rasuli
Journal:  Hepat Med       Date:  2012-08-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.